Pharminent

Precision Therapy Proves Effective in Treatment-Resistant Subgroup of COPD Patients

NewsCOPD, a progressive lung disease characterized by airway obstruction and chronic lung inflammation, affects 30 million Americans.Contributed Author: University of Pittsburgh School of Health SciencesTopics: Drug Discovery https://www.dddmag.com/news/2017/09/precision-therapy-proves-effective-treatment-resistant-subgroup-copd-patients

Filed under: COPD

Theravance COPD drug clears safety study, setting up NDA

Theravance Biopharma and Mylan are still on course to file for approval of their nebulized chronic obstructive pulmonary disease (COPD) therapy in the fourth quarter after posting 12-month safety data. The trial suggests revefenacin has a tolerable safety profile comparable to that of Boehringer Ingelheim’s bronchodilator Spiriva. http://www.fiercebiotech.com/biotech/theravance-copd-drug-clears-safety-study-setting-up-nda

Filed under: COPD

Add-on azithromycin cuts asthma exacerbations

FROM THE LANCET Adults with persistent symptomatic asthma who took azithromycin as an add-on therapy experienced fewer exacerbations and had … http://www.pm360online.com/add-on-azithromycin-cuts-asthma-exacerbations/

Filed under: Respiratory

NICE recommends AstraZeneca lung treatment

AstraZeneca’s Daxas (roflumilast) has received recommendation from NICE for the treatment of chronic obstructive pulmonary disease (COPD) is has emerged, meaning the therapy could soon be available for routine use on the NHS. The assessment covers adults whose severe COPD has not responded to other treatments.
read more http://www.pharmafile.com/news/514510/nice-recommends-astrazeneca-lung-treatment

Filed under: COPD

Chiesi backs up COPD triple therapy with real world study

Italian firm takes on mighty GSK
The post Chiesi backs up COPD triple therapy with real world study appeared first on Pharmaphorum. https://pharmaphorum.com/news/chiesi-looks-real-world-study-copd-contender/

Filed under: COPD

GOLD guidelines for the management of COPD – 2017 update

Chronic obstructive lung disease (COPD) is the third leading cause of death in the United States1 and a major cause of mortality and morbidity around the world. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) released a new “2017 Report”2 with modified recommendations for the diagnosis, management, and prevention of COPD. The report contains […] http://www.pm360online.com/gold-guidelines-for-the-management-of-copd-2017-update/

Filed under: COPD

Pieris teams up with AstraZeneca on respiratory drug development

The collaboration with the British pharma is Pieris’ second alliance signed this year, part of a push to accelerate development of the biotech’s platform technology. http://www.biopharmadive.com/news/pieris-astrazeneca-collaboration-respiratory-anticalin/441851/

Filed under: Respiratory

Circassia signs deal for US rights to two AstraZeneca COPD drugs

UK-based Circassia Pharmaceuticals has agreed to pay up to $230m for certain US commercial rights for Tudorza and Duaklir, two drugs developed by AstraZeneca to treat chronic obstructive pulmonary disease (COPD). http://drugdiscovery.pharmaceutical-business-review.com/news/circassia-secures-us-rights-for-two-astrazeneca-copd-drugs-for-230m-200317-5766626

Filed under: COPD

Boehringer signs COPD research deal with Weill

Boehringer Ingelheim and Weill Cornell Medicine are working together to identify novel treatment approaches that could halt or even reverse lung tissue damage in coronary obstructive pulmonary disorder (COPD). http://www.pharmatimes.com/news/boehringer_signs_copd_research_deal_with_weill_1186847

Filed under: COPD

Propeller Health, Novartis to Develop Add-On Sensor for Breezhaler

Propeller Health, a Madison, WI-based startup that makes Internet-connected inhalers and sensors designed to help asthma and chronic obstructive pulmonary disease (COPD) patients, says it is teaming up with Novartis to build an add-on sensor for the Swiss pharma giant’s Breezhaler device. The agreement, announced on Wednesday, is focused on patients with COPD who live […] http://www.xconomy.com/wisconsin/2017/02/08/propeller-health-novartis-to-develop-add-on-sensor-for-breezhaler/

Filed under: COPD

NICE supports use of asthma smartinhaler

NICE has published a Medtech Innovation Briefing recognising that Adherium’s Smartinhaler technology is more effective in improving adherence to asthma medication than current NHS practice. http://www.pharmatimes.com/news/nice_supports_use_of_asthma_smartinhaler_1183900

Filed under: Respiratory

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will
improve clinical trial engagement http://www.pmlive.com/pharma_news/gsk_targets_copd_adherence_with_integrated_inhaler_sensors_1183188

Filed under: COPD

Novartis out-licenses three COPD products in the US

EAST HANOVER, N.J., Dec. 21, 2016 /PRNewswire/ — Novartis announced today that it has signed a licensing agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for the US commercial rights to its three treatments for chronic obstructive pulmonary disease (COPD),  Utibron™ Neohaler® (inda… http://www.prnewswire.com/news-releases/novartis-out-licenses-three-copd-products-in-the-us-300382452.html

Filed under: COPD

GSK commences phase III study for triple combination asthma therapy

GlaxoSmithKline (GSK) and Innoviva have started started a triple combination therapy phase III study for the treatment of asthma. http://processandproduction.pharmaceutical-business-review.com/news/gsk-commences-phase-iii-study-for-triple-combination-asthma-therapy-201216-5701328

Filed under: Respiratory

GSK seeks EU approval for inhaled triple combo COPD therapy

GlaxoSmithKline (GSK) is seeking approval in Europe for once-daily closed triple combination therapy to treat chronic obstructive pulmonary disease (COPD) patients. http://www.pharmaceutical-business-review.com/news/gsk-and-innoviva-seek-eu-approval-for-copd-therapy-candidate-051216-5687325

Filed under: COPD

GSK files first application for triple COPD therapy

Submits combo in the US one year early to coincide with EU marketing application http://www.pmlive.com/pharma_news/gsk_files_first_application_for_triple_copd_therapy_1177783

Filed under: COPD

Asthma Research Yields New Treatment Approach for Inherited Enzyme Disease

NewsThe study results address Gaucher’s disease.Contributed Author: NYU Langone Medical CenterTopics: Disease Research http://www.dddmag.com/news/2016/10/asthma-research-yields-new-treatment-approach-inherited-enzyme-disease

Filed under: Respiratory

Theravance and Mylan’s COPD treatment shows benefits in phase 3 trials

A drug that is being developed by Theravance Biopharma and Mylan has shown promise in two phase 3 efficacy studies treating patients with chronic obstructive pulmonary disease. http://clinicaltrials.pharmaceutical-business-review.com/news/theravance-and-mylans-copd-treatment-shows-benefits-in-phase-3-trials-211016-5039060

Filed under: COPD

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk

RIDGEFIELD, Conn., Oct. 17, 2016 /PRNewswire/ — Boehringer Ingelheim today announced new data analyses from the Phase III TONADO® 1&2 trials that build upon existing evidence about the factors that increase the risk of a COPD exacerbation. These data were presented today at the… http://www.prnewswire.com/news-releases/new-data-analyses-provide-insights-that-may-help-predict-copd-exacerbation-risk-300345675.html

Filed under: COPD

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British
Lung Foundation and MRC Technology http://www.pmlive.com/pharma_news/astrazeneca_to_explore_link_between_epigenetics_and_respiratory_diseases_1124048

Filed under: Respiratory

Categories